Compile Data Set for Download or QSAR
Report error Found 172 Enz. Inhib. hit(s) with all data for entry = 12099
TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677971(US20240174679, Example 1-19 | methyl 1-methyl- 4-(...)
Affinity DataIC50: 2.19nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678004(US20240174679, Example 3-2 | N-(1-cyclobutyl- 3-cy...)
Affinity DataIC50: 4.47nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678101(US20240174679, Example 9-27 | N-(1-cyclobutyl- 1H-...)
Affinity DataIC50: 5.62nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677990(US20240174679, Example 1-38 | N-[1- cyclopropyl-3-...)
Affinity DataIC50: 5.89nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677965(US20240174679, Example 1-13 | N-(3-carbamoyl- 1-me...)
Affinity DataIC50: 6.76nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677956(US20240174679, Example 1-4 | N-[1-methyl-3- (methy...)
Affinity DataIC50: 7.08nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678060(US20240174679, Example 7-33 | N-[1- (cyclopropylme...)
Affinity DataIC50: 7.41nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678095(US20240174679, Example 9-21 | N-(1-cyclobutyl- 1H-...)
Affinity DataIC50: 8.32nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677960(US20240174679, Example 1-8 | 2-(1H-pyrazol-4- yl)-...)
Affinity DataIC50: 8.51nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678083(US20240174679, Example 9-9 | N-(1-cyclobutyl- 1H-p...)
Affinity DataIC50: 9.12nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678065(US20240174679, Example 7-38 | N-[1- (cyclopropylme...)
Affinity DataIC50: 9.55nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677854(US20240174679, Example 1-1 | N-(1-Cyclobutyl-1H-py...)
Affinity DataIC50: 9.77nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678077(US20240174679, Example 9-3 | N-(1-cyclobutyl- 1H-p...)
Affinity DataIC50: 9.77nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677984(US20240174679, Example 1-32 | N-{1-[(3,3- dimethyl...)
Affinity DataIC50: 10nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678008(US20240174679, Example 4-1 | Scheme 15. Synthesis ...)
Affinity DataIC50: 10.5nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677983(US20240174679, Example 1-31 | N-(1,1'-dimethyl- 1H...)
Affinity DataIC50: 11.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677986(US20240174679, Example 1-34 | N-{1-[(1- methylcycl...)
Affinity DataIC50: 12nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678041(US20240174679, Example 7-14 | N-[1- (cyclopropylme...)
Affinity DataIC50: 12nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677996(US20240174679, Example 1-44 | N-[1-({1- [(methylsu...)
Affinity DataIC50: 12.3nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677963(US20240174679, Example 1-11 | N-[3-(4- fluoropheny...)
Affinity DataIC50: 12.6nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678071(US20240174679, Example 8-1 | Scheme 19. Synthesis ...)
Affinity DataIC50: 12.6nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678073(US20240174679, Example 8-3 | N-{1-[2-(1- methyleth...)
Affinity DataIC50: 12.9nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50590210(CHEMBL5205763 | US20240174679, Example 9-28)
Affinity DataIC50: 14.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677958(US20240174679, Example 1-6 | N-(1,3- dicyclopropyl...)
Affinity DataIC50: 14.5nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678120(US20240174679, Example 12-3 | N-(1,3- dicyclopropy...)
Affinity DataIC50: 14.5nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677955(US20240174679, Example 1-3 | N-(1-Cyclobutyl-3-met...)
Affinity DataIC50: 14.8nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677981(US20240174679, Example 1-29 | N-(1-{[1- (methoxyme...)
Affinity DataIC50: 15.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678074(US20240174679, Example 8-4 | N-[1-(2,6- dimethylpy...)
Affinity DataIC50: 15.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678046(US20240174679, Example 7-19 | N-[1- (cyclobutylmet...)
Affinity DataIC50: 15.8nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677967(US20240174679, Example 1-15 | N-[3- (difluoromethy...)
Affinity DataIC50: 16.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677982(US20240174679, Example 1-30 | N-(1-methyl-3- pheno...)
Affinity DataIC50: 16.6nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678056(US20240174679, Example 7-29 | N-{1-[(2,2- difluoro...)
Affinity DataIC50: 16.6nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677979(US20240174679, Example 1-27 | N-[1-({1- [(methylsu...)
Affinity DataIC50: 17nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677987(US20240174679, Example 1-35 | N-{1-[(3,3- difluoro...)
Affinity DataIC50: 17nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677974(US20240174679, Example 1-22 | N-(1-cyclobutyl- 3-m...)
Affinity DataIC50: 17.4nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678028(US20240174679, Example 7-1 | Scheme 18. Synthesis ...)
Affinity DataIC50: 17.4nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678044(US20240174679, Example 7-17 | N-[1-(4- fluorobenzy...)
Affinity DataIC50: 17.4nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678084(US20240174679, Example 9-10 | N-[1- (cyclobutylmet...)
Affinity DataIC50: 17.4nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678119(US20240174679, Example 12-2 | N-(1-cyclobutyl-3- c...)
Affinity DataIC50: 17.4nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678036(US20240174679, Example 7-9 | N-[3- (difluoromethyl...)
Affinity DataIC50: 17.8nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677994(US20240174679, Example 1-42 | N-(3- cyclopropyl-1-...)
Affinity DataIC50: 18.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678066(US20240174679, Example 7-39 | N-{1-[(2,2- difluoro...)
Affinity DataIC50: 18.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678072(US20240174679, Example 8-2 | N-[1-(3- methylpyridi...)
Affinity DataIC50: 18.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678118(US20240174679, Example 12-1 | Scheme 23. Synthesis...)
Affinity DataIC50: 18.2nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678034(US20240174679, Example 7-7 | N-[3- (difluoromethyl...)
Affinity DataIC50: 19.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678045(US20240174679, Example 7-18 | N-[3- (difluoromethy...)
Affinity DataIC50: 19.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678064(US20240174679, Example 7-37 | N-{1-[(4- cyanocyclo...)
Affinity DataIC50: 19.1nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678052(US20240174679, Example 7-25 | N-{1-[(1- cyanocyclo...)
Affinity DataIC50: 20nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM677972(US20240174679, Example 1-20 | N-[1-(1- methylethyl...)
Affinity DataIC50: 20.9nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

TargetLeucine-rich repeat serine/threonine-protein kinase 2(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM678039(US20240174679, Example 7-12 | N-[3- (difluoromethy...)
Affinity DataIC50: 20.9nMAssay Description:IC50 (half-maximal inhibitory concentration) represents the concentration of inhibitor required to inhibit LRRK2 kinase activity by 50%. Assays were ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 172 total ) | Next | Last >>
Jump to: